Botulinum Toxin Type A

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Botulinum Toxin Type A
   1. Pharmacist Assessment Report
   2. Botulinum Toxin Type A: Known uses and market status in Australia
   3. Summary
   4. Quick overview
   5. Known uses recorded for this drug
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Australia Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Botulinum Toxin Type A: Known uses and market status in Australia

Summary

The TxGNN deep-learning model has no candidate with a score of 0.99 or higher for Botulinum Toxin Type A, so there is currently no new predicted indication. The drug’s recorded uses are listed below.

Quick overview

Item	Content
New predicted indications	None (no model candidate scored 0.99 or higher)
Known uses recorded for this drug	1
Evidence level	Not applicable
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)

Known uses recorded for this drug

Approved (supported by a licence or label)

Indication	Source
skin aging	licence in another country

Related to an approved indication (same disease category)

Indication	Approved category
none	none

Relations recorded in the knowledge graph (no approval found)

Indication
none

Australia Market Information

Licence	Product	Dosage form	Status
10993N	Botox	Lyophilised powder for injection 100 uni	Valid

Safety Considerations

Drug Interactions (41 interactions identified, mainly from DDInter):

• Major: aminoglycosides and related agents (kanamycin, neomycin, streptomycin) and polymyxin B. These may potentiate neuromuscular blockade.
• Moderate: anticholinergics (atropine, clidinium, dicyclomine, glycopyrronium, hyoscyamine, mepenzolate, methscopolamine, propantheline, scopolamine, trospium) and sedating antihistamines (promethazine, acrivastine, azatadine, brompheniramine, carbinoxamine, chlorcyclizine).

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications, which were not available in the data compiled.

---

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---